Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 18, 2026, where stockholders will vote on director elections, ratification of WithumSmith+Brown, PC as auditor, an advisory vote on executive compensation, approval of an amended 2018 Equity Incentive Plan, and a proposed reverse stock split at a ratio between 1:5 and 1:50 (to be implemented at the Board’s discretion any time prior to December 31, 2027).
The record date for voting is April 24, 2026. The proxy materials, including the Company’s 2025 Annual Report on Form 10-K, will be mailed beginning on or about April (date omitted). The Board recommends voting FOR the named director nominees and the listed proposals.
Genprex, Inc. director Brent M. Longnecker reported small open-market sales of Genprex common stock, primarily for tax purposes. On April 14, 2026, he sold 8 shares of common stock at $1.23 per share from his direct holdings and 10 shares at $1.23 per share through indirect ownership by Longnecker Associates Ltd. Following these transactions, he directly holds 9,157 shares of Genprex common stock, with no remaining indirect shares reported in this filing.
Genprex, Inc. is a clinical-stage gene therapy company developing REQORSA for lung cancer and GPX-002 for Type 1 and Type 2 diabetes. REQORSA, delivered with the non-viral ONCOPREX system, is in Phase 2a Acclaim-1 for EGFR-mutant NSCLC and Phase 2 Acclaim-3 for extensive-stage small cell lung cancer, both with FDA Fast Track status and Orphan Drug Designation in SCLC.
The company is advancing preclinical GPX-002 diabetes programs after an FDA meeting in February 2026 on IND-enabling studies. Genprex strengthened liquidity via an at-the-market program, raising about $10.8 million in 2025 and $13.3 million through early 2026, executed two reverse stock splits to support Nasdaq listing, and regained compliance with Nasdaq equity and bid price rules. As of March 27, 2026, it had 9,044,856 common shares outstanding and a non-affiliate equity market value of about $7.5 million as of June 30, 2025.
Genprex, Inc. reported that its research collaborators will present three posters at the 2026 AACR Annual Meeting featuring new preclinical data on its lead candidate, REQORSA (quaratusugene ozeplasmid, “Quar Oze”), for non-small cell lung cancer.
The first study identifies TROP2 and PTEN expression patterns as potential biomarkers of primary resistance to TUSC2 gene therapy across NSCLC cell lines, organoids and xenograft models, helping explain which tumors may not respond.
The second study shows Quar Oze-driven TUSC2 overexpression induces strong tumor cell death in ALK-positive NSCLC models and enhances the effect of the ALK inhibitor alectinib, including in alectinib-resistant tumors, with combination treatment achieving the greatest tumor shrinkage and survival benefits in mice.
The third study demonstrates that restoring TUSC2 via Quar Oze boosts natural killer (NK) cell cytotoxicity, improves antitumor immune responses and, in many cases, leads to complete tumor regression in mouse models, supporting TUSC2 as both a tumor suppressor and immunomodulatory target.
Genprex, Inc.’s Chief Medical Officer, Mark Stanley Berger, reported a tax-related share withholding. On February 27, 2026, 7,168 shares of common stock were withheld to cover tax obligations tied to the vesting of Restricted Stock Units granted under Genprex’s 2018 Equity Incentive Plan. After this tax-withholding disposition, he directly owned 21,692 shares of Genprex common stock.
Genprex, Inc. director and executive officer Ryan M. Confer reported a Form 4 transaction showing a tax-withholding disposition of 9,330 shares of common stock at $2.00 per share. According to the disclosure, these shares were withheld on February 27, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units granted under the company’s 2018 Equity Incentive Plan. After this withholding, Confer directly holds 36,331 shares of Genprex common stock.
Genprex, Inc. reported that the Japanese Patent Office issued a favorable appeal decision to grant a patent covering use of REQORSA Gene Therapy with PD‑L1 antibodies to treat cancer, and the European Patent Office issued a decision to grant a patent for REQORSA in combination with PD‑1 antibodies. Genprex holds an exclusive license to these patents and states they strengthen protection for therapeutic combinations, including its Acclaim‑3 trial in small cell lung cancer.
The company notes it already has granted patents for REQORSA and PD‑L1 combinations in the U.S. and Korea, with a pending grant in Australia, and REQORSA and PD‑1 combinations in multiple regions including the U.S., Japan and the EU. Acclaim‑3 is a Phase 1/2 trial of REQORSA plus Genentech’s Tecentriq as maintenance therapy for extensive‑stage small cell lung cancer. The Phase 2 expansion is expected to enroll about 50 patients, with an interim analysis planned after the 25th patient has 18 weeks of follow‑up. Genprex expects to complete enrollment of the first 25 patients in the first half of 2026 and conduct the interim analysis in the second half of 2026. The trial has U.S. FDA Fast Track and Orphan Drug designations.
Genprex, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri together report beneficial ownership of 249,788 shares of Genprex common stock through warrants. This position represents 9.72% of the common stock, calculated using 2,318,894 shares outstanding as of November 19, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how many shares can be issued on exercise at any time. The investors certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Genprex.
Genprex, Inc. reported that IP Australia issued a Notice of Acceptance for its patent application covering the use of REQORSA Gene Therapy with PD-L1 antibodies to treat cancers. If granted, this patent would secure exclusivity for this drug combination in Australia and strengthen Genprex’s intellectual property portfolio alongside granted patents in the U.S. and Korea.
The company is also pursuing additional patent applications in Europe, Canada, Brazil, China and Israel and has opened a new Acclaim-3 clinical trial site at the University of Kentucky. Acclaim-3 is a Phase 1/2 trial of REQORSA plus Tecentriq as maintenance therapy for extensive stage small cell lung cancer, supported by FDA Fast Track and Orphan Drug Designations.
The Phase 2 expansion is expected to enroll about 50 patients, with an interim analysis planned after the 25th patient reaches 18 weeks of follow-up. Genprex expects to complete enrollment of these 25 patients in the first half of 2026 and conduct the interim analysis in the second half of 2026.
Genprex, Inc. reported that Nasdaq’s Hearings Panel has determined the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. This restores the company’s standing with Nasdaq’s equity requirement after a prior deficiency notice received on August 19, 2025.
Under Nasdaq Listing Rule 5815(d)(4)(B), Genprex will be under a mandatory panel monitor through January 7, 2027. If during this one-year period Nasdaq staff again finds the company out of compliance with the same minimum stockholders’ equity rule, staff will issue a delisting determination without providing an additional cure period or plan-of-compliance process, although Genprex would be able to request a new hearing and its securities could then be delisted from Nasdaq.